CD34 and heart failure: These four points: CD34+ stem cells; high cell doses; intramyocardial injection route; and acute or sub-acute myocardial ischemia indication, appear as to be the key factors that allow avoiding secondary heart failure, which is very difficult to effectively treat and is associated with a short/middle term bad prognosis (Fig. 2).